我国疑似预防接种异常反应补偿制度的探讨

doi:10.19803/j.1672-8629.2021.04.07

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (4): 328-333.
DOI: 10.19803/j.1672-8629.2021.04.07

我国疑似预防接种异常反应补偿制度的探讨

仲志磊, 尹兴晓, 梁燕, 石昊昱, 付杰, 杨净思^*

中国医学科学院医学生物学研究所,云南昆明 650118

收稿日期:2020-09-10 出版日期:2021-04-15 发布日期:2021-04-23
通讯作者: ^*杨净思,男,研究员,病原学与疫苗学。E-mail：yjs@imbcams.com.cn
作者简介:仲志磊,男,硕士,助理研究员,不良反应调查与药物警戒。

Discussion on the Treatment Mechanism of Adverse Events Following Immunization in China

ZHONG Zhilei, YIN Xingxiao, LIANG Yan, SHI Haoyu, FU Jie, YANG Jingsi^*

Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming Yunnan 650118, China

Received:2020-09-10 Online:2021-04-15 Published:2021-04-23

摘要/Abstract

摘要： 目的对比世界卫生组织（WHO）25个成员国家因疫苗接种造成损害建立的补偿制度,研究2019版《中华人民共和国疫苗管理法》（简称“《疫苗法》”）中的相关条款,为完善我国疑似预防接种异常反应(AEFI)补偿制度提供思路。方法综合运用情报调研、文献定性分析方法,对比美国、新西兰、日本和欧洲等疫苗损害补偿制度的特点,研究分析我国《疫苗法》相应条款。结果各国疫苗损害补偿制度各有利弊,我国《疫苗法》对AEFI补偿制度提出了指导性意见,但尚缺乏与之相应的补偿条例和细则。结论建议我国按照《疫苗法》的相关规定,尽快出台全国统一的补偿制度细则,建立多方筹措补助基金机制,保障各方利益,维护和谐的疫苗使用环境。

关键词: 疫苗, 疑似预防接种异常反应, 疫苗法, 补偿制度

Abstract: Objective Comparing the vaccine injury relief system established by the damage caused by vaccination in 25 typical countries of the World Health Organization, Studying the relevant provisions in the "Vaccine Administration Law", provides ideas for the AEFI compensation system. Methods Using intelligence research and literature qualitative analysis methods to compare and analyze the characteristics of vaccine injury rescue mechanisms in the United States, New Zealand, Europe, and Japan. Studying and analyzing the corresponding provisions of the 2019 Vaccine Law. Results Each country’s vaccine injury treatment mechanism has its own advantages and disadvantages. China 2019 Vaccine Law provides guiding opinions on AEFI compensation, but there is still a lack of corresponding rescue regulations and rules. Conclusion In accordance with the relevant provisions of the 2019 Vaccine Law, China should introduce a unified national rescue system and detailed rules as soon as possible, consider raising subsidy funds from multiple sources, protect the interests of all parties, and maintain a harmonious vaccine use environment.

Key words: vaccines, AEFI, vaccine law, compensation system

中图分类号:

R994.11

仲志磊, 尹兴晓, 梁燕, 石昊昱, 付杰, 杨净思. 我国疑似预防接种异常反应补偿制度的探讨[J]. 中国药物警戒, 2021, 18(4): 328-333.

ZHONG Zhilei, YIN Xingxiao, LIANG Yan, SHI Haoyu, FU Jie, YANG Jingsi. Discussion on the Treatment Mechanism of Adverse Events Following Immunization in China[J]. Chinese Journal of Pharmacovigilance, 2021, 18(4): 328-333.

参考文献

[1] Looker C, Kelly H.No-fault compensation following adverse events attributed to vaccination: a reviewof international programmes[J]. Bull World Health Organ, 2011, 89: 371-378.
[2] Cook KM, Evans G.The national vaccine injury compensation program[J]. Pediatrics, 2011, 127(Suppl1) S74-S77.
[3] Mungwira RG, Guillard C, Saldaa A, et al.Global landscape analysis of no-fault compensation programmes for vaccine injuries: A review and survey of implementing countries[J]. PLoS One, 2020, 15(5): e0233334.
[4] Fei L, Peng Z.No-fault compensation for adverse events following immunization: A review of chinese law and practice[J]. Medical Lawreview, 2017, 25(1): 99-114.
[5] Ihara T.The national vaccine injury compensation program in Japan[J]. Nihon Rinsho Japanese Journal of Clinical Medicine, 2011, 69(9): 1645-1650.
[6] Kim MK, Lee YK, Kim TE, et al.Surveillance and compensation claims for adverse events following immunization from 2011 to 2016 in the Republic of Korea[J]. Clinical and Experimental Vaccine Research 2017, 6(2): 146-155.
[7] Thompson KM, Orenstein WA, Hinman AR.Performance of the united states vaccine injury compensation program (VICP): 1988-2019[J]. Vaccine, 2020, 38( 9): 2136-2143.
[8] Anne-Maree F, Sarah D, Amber D, No-fault compensation schemes for medical injury: A Review[J]. SSRN Electronic Journal, 2010. DOI: 10. 2139/ssrn. 2221836
[9] Mungwira RG. Maure CG, Zuber PLF.Economic and immunisation safety surveillance characteristics of countries implementing no-fault compensation programmes for vaccine injuries[J]. Vaccine, 2019, 37(31): 4370-4375.
[10] Nelson MR.A no-fault compensation scheme for serious adverse events attributed to vaccination[J]. The Medical Journal of Australia, 2011, 195(5): 263.
[11] Hrsa RSA.National Vaccine Injury Compensation Program: revisions to the vaccine injury table. Final rule.[J]. Federal Register, 2011, 82(120): 6294-6305.
[12] Zhang Z. Vaccine Litigation:reality and fiction in American courts [N/OL]. Sciencene(科学网),[2017-05-07]. http://news.sciencenet.cn/htmlnews/2017/5/375414.shtm.
[13] Yang Y.Speed up the formulation of "Vaccine administration law of the people's Republic of China " and improve the compensation mechanism of vaccine abnormal reaction[J]. China Food & Drug Administration Magazine(中国食品药品监管), 2019(3): 4-9.
[14] Vaccine administration law of the people's Republic of China [N]. The People's Daily(人民日报), 2019-08-14(14).
[15] Ministry of health of China. National surveillance program for suspected adverse reactions to vaccination[J]. Chinese Journal of Vaccines and Immunization(中国疫苗和免疫), 2011, 17(1):72-81.
[16] Wang YF,Yang LN,Yang Y.Study on vaccine injury compensation trust fund in the United States and its enlightenment to China[J]. China Pharmacy(中国药房),2020, 31(12): 1419-1424.
[17] Ding CY.The establishment of national compensation system of adverse event following immunization: Comparative analysis based on different local compensation standards[J]. Chinese Health Economics(中国卫生经济), 2018, 37(11): 5-8.

我国疑似预防接种异常反应补偿制度的探讨

Discussion on the Treatment Mechanism of Adverse Events Following Immunization in China

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	高旭, 彭金娥, 李兴旺, 张伟. 猴痘抗病毒药物及疫苗研究现状[J]. 中国药物警戒, 2024, 21(1): 111-116.
[2]	资文瑞, 杨秋月, 苏俊, 谢江安. 我国上市人乳头瘤病毒疫苗接种及安全性研究[J]. 中国药物警戒, 2023, 20(3): 311-316.
[3]	赵欢欢, 宋佳伟, 刘金广, 黄明辉. 狂犬病疫苗致5岁儿童肾病综合征1例分析[J]. 中国药物警戒, 2023, 20(11): 1303-1305.
[4]	吴昀效, 于玥琳, 王胜锋, 孙凤, 孟若谷, 詹思延. 真实世界数据在疫苗上市后安全性主动监测中适用性评价分析[J]. 中国药物警戒, 2023, 20(10): 1081-1089.
[5]	杨秋月, 苏俊, 张雪, 谢江安. 基于VAERS数据库的三类美国上市新型冠状病毒疫苗不良事件分析[J]. 中国药物警戒, 2023, 20(10): 1141-1147.
[6]	孙一鑫, 刘志科, 詹思延. 疫苗上市后安全性准实时监测的概括性评价[J]. 中国药物警戒, 2023, 20(1): 61-67.
[7]	冯菁楠, 赵厚宇, 刘志科, 詹思延. 自身对照树状时间扫描统计量在疫苗安全性监测中的应用[J]. 中国药物警戒, 2023, 20(1): 68-73.
[8]	刘志科, 詹思延. 自身对照设计在疫苗安全性关联研究中的应用进展[J]. 中国药物警戒, 2023, 20(1): 74-78.
[9]	刘砚韬, 张伶俐, 林芸竹, 陈力, 王丽. 基于美国疫苗不良事件报告系统的肺炎疫苗不良反应信号挖掘与研究[J]. 中国药物警戒, 2023, 20(1): 96-100.
[10]	潘雪娇, 沈灵智, 梁辉, 唐学雯, 符剑, 丁林玲, 吕华坤. 浙江省肠道病毒71型疫苗上市后AEFI监测与评价[J]. 中国药物警戒, 2022, 19(8): 897-899.
[11]	鲍柏屹, 汤贯光, 王兴伟, 唐书炳, 李歆, 韩峰. 新型抗肿瘤免疫治疗药物研究进展[J]. 中国药物警戒, 2021, 18(8): 719-724.
[12]	陈爱宏, 尹强兵, 李华丹, 吴能简. 2015~2018年深圳市坪山区疑似预防接种异常反应监测报告分析[J]. 中国药物警戒, 2021, 18(5): 464-468.
[13]	于一, 王亚丽. 疫苗国家监管体系评估的警戒板块要求浅析与启示[J]. 中国药物警戒, 2021, 18(4): 324-327.
[14]	王远征, 刘波, 邓霞, 高晨燕, 杨焕. 预防用疫苗说明书安全性有关内容的思考[J]. 中国药物警戒, 2021, 18(4): 334-337.
[15]	王亚丽. 疫苗增强性疾病风险探讨[J]. 中国药物警戒, 2021, 18(4): 338-340.